Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy

Cancer Treatment and Research

WILLIAM L MCGUIRE, series editor

Livingston RB (ed): Lung Cancer 1. 1981. ISBN 90-247-2394-9.

Bennett Humphrey G, Dehner LP, Grindey GB, Acton RT (eds): Pediatric Oncology 1. 1981. ISBN 90-247-2408-2.

DeCosse JJ, Sherlock P (eds): Gastrointestinal Cancer 1. 1981. ISBN 90-247-2461-9.

Bennett JM (ed): Lymphomas 1, including Hodgkin's Disease. 1981. ISBN 90-247-2479-1.

Bloomfield CD (ed): Adult Leukemias 1. 1982. ISBN 90-247-2478-3.

Paulson DF (ed): Genitourinary Cancer 1. 1982. ISBN 90-247-2480-5.

Muggia FM (ed): Cancer Chemotherapy 1. ISBN 90-247-2713-8.

Bennett Humphrey G, Grindey GB (eds): Pancreatic Tumors in Children. 1982. ISBN 90-247-2702-2.

Costanzi JJ (ed): Malignant Melanoma 1. 1983. ISBN 90-247-2706-5.

Griffiths CT, Fuller AF (eds): Gynecologic Oncology. 1983. ISBN 0-89838-555-5.

Greco AF (ed): Biology and Management of Lung Cancer. 1983. ISBN 0-89838-554-7.

Walker MD (ed): Oncology of the Nervous System. 1983. ISBN 0-89838-567-9.

Higby DJ (ed): Supportive Care in Cancer Therapy. 1983. ISBN 0-89838-569-5. Herberman RB (ed): Basic and Clinical Tumor Immunology. 1983. ISBN 0-89838-579-2.

Baker LH (ed): Soft Tissue Sarcomas. 1983. ISBN 0-89838-584-9.

Bennett JM (ed): Controversies in the Management of Lymphomas. 1983. ISBN 0-89838-586-5.

Bennett Humphrey G, Grindey GB (eds): Adrenal and Endocrine Tumors in Children. 1983. ISBN 0-89838-590-3.

DeCosse JJ, Sherlock P (eds): Clinical Management of Gastrointestinal Cancer. 1984. ISBN 0-89838-601-2.

Catalona WJ, Ratliff TL (eds): Urologic Oncology. 1984. ISBN 0-89838-628-4.

Santen RJ, Manni A (eds): Diagnosis and Management of Endocrine-related Tumors. 1984. ISBN 0-89838-636-5.

Costanzi JJ (ed): Clinical Management of Malignant Melanoma. 1984. ISBN 0-89838-656-X.

Wolf GT (ed): Head and Neck Oncology. 1984. ISBN 0-89838-657-8.

Alberts DS, Surwit EA (eds): Ovarian Cancer. 1985. ISBN 0-89838-676-4.

Muggia FM (ed): Experimental and Clinical Progress in Cancer Chemotherapy. 1985. ISBN 0-89838-679-9.

Higby DJ (ed): The Cancer Patient and Supportive Care. 1985. ISBN 0-89838-690-X.

Bloomfield CD (ed): Chronic and Acute Leukemias in Adults. 1985. ISBN 0-89838-702-7.

Herberman RB (ed): Cancer Immunology: Innovative Approaches to Therapy. 1986. ISBN 0-89838-757-4.

Hansen HH (ed): Lung Cancer: Basic and Clinical Aspects. 1986. ISBN 0-89838-763-9.

Pinedo HM, Verweij J (eds): Clinical Management of Soft Tissue Sarcomas. 1986. ISBN 0-89838-808-2.

Higby DJ (ed): Issues in Supportive Care of Cancer Patients. 1986. ISBN 0-89838-816-3.

Surwit EA, Alberts DS (eds): Cervix Cancer. 1987. ISBN 0-89838-822-8.

Jacobs C (ed): Cancers of the Head and Neck. 1987. ISBN 0-89838-825-2.

MacDonald JS (ed): Gastrointestinal Oncology. 1987. ISBN 0-89838-829-5.

Ratliff TL, Catalona WJ (eds): Genitourinary Cancer. 1987. ISBN 0-89838-830-9.

Nathanson L (ed): Basic and Clinical Aspects of Malignant Melanoma. 1987. ISBN 0-89838-856-2.

Muggia FM (ed): Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy. 1987. ISBN 0-89838-879-5.

Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy

edited by

F.M. MUGGIA

University of Southern California Cancer Center 1441 Eastlake Avenue Los Angeles, California 90033 USA



Distributors

for the United States and Canada: Kluwer Academic Publishers, 101 Philip Drive, Assinippi Park, Norwell, MA 02061, USA for the UK and Ireland: Kluwer Academic Publishers, MTP Press Limited, Falcon House, Queen Square, Lancaster LA1 1RN, UK for all other countries: Kluwer Academic Publishers Group, Distribution Center, P.O. Box 322, 3300 AH Dordrecht, The Netherlands

Library of Congress Cataloging-in-Publication Data

Concepts, clinical developments, and therapeutic advances in cancer chemotherapy.

(Cancer treatment and research)

1. Cancer—Chemotherapy. 2. Antineoplastic agents.

I. Muggia, Fanco M. II. Series. [DNLM: 1. Antineoplastic

Agents—therapeutic use. 2. Neoplasms—drug therapy.

W1 CA693 / QZ 267 C744]

RC271.C5C65 1987 616.99'4061 87-7754

ISBN-13: 978-1-4612-9204-3 e-ISBN-13: 978-1-4613-2021-0

DOI: 10.1007/978-1-4613-2021-0

Copyright

© 1987 by Martinus Nijhoff Publishers, Boston.

Softcover reprint of the hardcover 1st edition 1987

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publishers,

Martinus Nijhoff Publishers, 101 Philip Drive, Assinippi Park, Norwell, MA 02061, USA.

Table of Contents

Foreword to the Series	vii
Preface	ix
List of Contributors	xi
I. Concepts	
 DNA filter elution methods in anticancer drug development K.W. KOHN 	3
 Intraperitoneal chomotherapy: Principles and results of clinical trials M. MARKMAN and S.B. HOWELL 	39
II. New Drugs and New Clinical Investigation	
 Metabolites of tiazofurin as mediators of its biochemical and pharmacologic effects. G.S. AHLUWALIA, H.N. JAYARAM and D.A. COONEY 	63
4. Extragonadal and central nervous system germ cell tumors: A review of diagnostic and therapeutic strategies E.L. FRIEDMAN and M.B. GARNICK	103
5. Role of preclinical pharmacology in phase I clinical trials: Considerations of schedule-dependence J.M. COLLINS, B. LEYLAND-JONES and C.K. GRIESHABER	129
6. Interferon: Current concepts of mechanisms of action P.P. TROTTA and R.J. SPIEGEL	141

7.	R. EARHART	161
III. Sp	ecific Therapeutic Landmarks	
8.	Chemotherapy for malignant intracranial tumors P. KORNBLITH and M. WALKER	185
9.	New antiviral compounds and impact in management of neoplastic disease and AIDS A. CHACHOUA and M. GREEN	205
10.	The clinical horizon of deoxycoformycin P.J. O'DWYER, B. LEYLAND-JONES and D.F. HOTH	233
Index		257

Cancer Treatment and Research

Foreword

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good indepth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered.

Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription.

We have approached the problem in the following fashion. First, by dividing the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more.

In Cancer Treatment and Research, we have an outstanding group of editors, each having made a major commitment to bring to this new series the very best literature in his or her field. Martinus Nijhoff Publishers has made an equally major commitment to the rapid publication of high quality books, and world-wide distribution.

Where can you go to find quickly a recent authoritative article on any major oncology problem? We hope that Cancer Treatment and Research provides an answer.

WILLIAM L. McGuire Series Editor

Preface

As in the preceding two volumes on cancer chemotherapy published in this series, this book represents but a glimpse at the vast and expanding area of cancer chemotherapy. When considered in its broadest sense, biologic response modifiers introduced to treat cancer in man are the latest class of agents being studied for their antiproliferative activities. It is fitting that the first of these drugs widely employed as a result of recombinant technology be reviewed in depth just as five years of investigational clinical experience have been completed. Although disappointing to those whose expected a universally successful translation of its heralded in vitro versatility, alpha interferon has established itself as an effective treatment of hairy cell leukemia and a promising adjunct in several other clinical areas. Coincidentally we review deoxycoformycin, which is also proving to be effective in hairy cell leukemia. Deoxycoformycin, while failing to live up to expectations of unprecedented selectivity against lymphoid tumors, also holds promise if we learn to respect its toxicities; and it holds great theoretical interest. Another drug covered in depth is tiazofurin. Although this compound has not proven to have clinical utility, the experience in phase I trials is instructive, and its mechanism of action has been investigated in detail. Its antiviral properties should also prove of interest in this era of burgeoning hopes of controlling retroviral and other viral infections. Since viral etiology of malignancy is coming into prominence with the acquired immunodeficiency syndromerelated neoplasms, future relationships between antitumor activity and antiviral properties might emerge.

The evolving concepts and technical applications of locoregional therapy are covered by the San Diego group of Drs. Markman and Howell, who provide the perspective of several years and, by now, hundreds of patients' experiences. The sound pharmacologic basis of this approach was developed less then a decade ago by workers at the National Cancer Institute. The advantage achieved by intraperitoneal administration of drugs has been carefully studied utilizing a range of agents, and its theoretical foundations have been amply confirmed. This review therefore constitutes an excellent example of the optimal interface between the laboratory and the clinic in establishing new therapeutic modalities.

Another aspect of experimental therapeutics deals with the interface of animal and human pharmacology in the planning and execution of phase I studies. More closely linked to the laboratory are the principles of biochemical modulation, many of which have not yet been successfully applied clinically. Finally, clinicians and experimentalists alike might be interested in the overview of the DNA alkaline elution technique in drug development by its initiator, Dr. Kurt Kohn and his colleauges.

The review of clinical applications of chemotherapy focuses on two distinct areas, each of which merits in-depth attention at this time. Brain tumors, which first yielded partially to chemotherapy more than 18 years ago, must be reevaluated with an eye towards capitalizing on recent advances in tumor biology. Mediastinal germ cell tumors represent a new entity which is now successfully treated with chemotherapy and is worthy of a thorough review. We hope that in-depth readers and surveyors of the chemotherapy field will find this blend of concepts, new clinical developments, and therapeutic landmarks useful to clinical and laboratory scientists on a recurrent basis.

F.M. Muggia, editor

List of contributors

- AHLUWALIA, GS, Gillette Research Institute, 1413 Research Boulevard, Rockville, MD 20850
- CHACHOUA, A, NYU Medical Center, 550 First Avenue, New York, NY 10016
- COLLINS, JM, Bldg 10, Rm 6N119, National Institutes of Health, Bethesda, MD 20892
- COONEY, DA, Laboratory of Pharmacology and Experimental Therpeutics, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892
- EARHART, RH, Cancer and Viral Diseases Research, The Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001
- FRIEDMAN, EL, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115
- GARNICK, MB, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115
- GREEN, MD, NYU Medical Center, 550 First Avenue, New York, NY 10016
- GRIESHABER, CK, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892
- HOTH, DF, Investigational Drug Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892
- HOWELL, SB, Cancer Center and The General Clinical Research Center, University of California, San Diego, La Jolla, CA 92093
- JAYARAM, HN, Laboratory of Experimental Oncology, Indiana University School of Medicine, 702 Barnhill Drive, Indianapolis, IN 46223
- KOHN, KW, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892
- KORNBLITH, PL, Department of Neurosurgery, Albert Einstein College of Medicine, Montefiore Medical Center, 110 E. 210 Street, Bronx, NY 10467
- LEYLAND-JONES, B, Investigational Drug Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892

- MARKMAN, M, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021
- O'DWYER, PJ, Division of Medical Oncology, Fox Chase Cancer Center, Central and Shelmire Avenues, Philadelphia, PA 19111
- SPIEGEL, RJ, Schering-Plough Corp. Bloomfield, NJ 07003
- TROTTA, PP, Schering-Plough Corp. Bloomfield, NJ 07003
- WALKER, M, National Institutes of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892